GMAB
Genmab AS
NASDAQ: GMAB · HEALTHCARE · BIOTECHNOLOGY
$26.11
-2.54% today
Updated 2026-04-29
Market cap
$16.45B
P/E ratio
17.40
P/S ratio
4.42x
EPS (TTM)
$1.54
Dividend yield
—
52W range
$19 – $35
Volume
1.7M
Genmab AS (GMAB) Financial statements
SEC filings — annual and quarterly data.
Profit margin
25.90%
Operating margin
23.00%
ROE
17.50%
ROA
8.10%
Debt/equity
0.02x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $135.55M | $-438.24M | 100.00% | -348.38% | -323.31% |
| 2007 | $529.54M | $-383.37M | 100.00% | -82.55% | -72.40% |
| 2008 | $745.11M | $-965.09M | 93.45% | -96.90% | -129.52% |
| 2009 | $586.08M | $-1.01B | 100.00% | -84.98% | -172.46% |
| 2010 | $582.08M | $-321.46M | -0.07% | -27.61% | -55.23% |
| 2011 | $350.94M | $-596.37M | -51.74% | -71.07% | -169.94% |
| 2012 | $484.64M | $-487.12M | 100.00% | -24.08% | -100.51% |
| 2013 | $663.57M | $112.36M | 100.00% | 10.44% | 16.93% |
| 2014 | $850.38M | $301.30M | 100.00% | 31.18% | 35.43% |
| 2015 | $1.13B | $763.51M | 100.00% | 64.46% | 67.39% |
| 2016 | $1.82B | $1.19B | 100.00% | 57.97% | 65.36% |
| 2017 | $2.37B | $1.10B | 100.00% | 56.83% | 46.65% |
| 2018 | $3.03B | $1.47B | 100.00% | 45.63% | 48.66% |
| 2019 | $5.37B | $2.17B | 100.00% | 49.16% | 40.37% |
| 2020 | $10.11B | $4.76B | 100.00% | 62.44% | 47.06% |
| 2021 | $8.42B | $2.96B | 100.00% | 35.08% | 35.13% |
| 2022 | $14.51B | $5.45B | 100.00% | 43.21% | 37.59% |
| 2023 | $16.47B | $4.35B | 98.63% | 32.30% | 26.42% |
| 2024 | $21.53B | $7.84B | 95.42% | 31.14% | 36.44% |
| 2025 | $3.72B | $963.76M | 91.69% | 33.60% | 25.89% |